5-amino-1MQ — what the research says about the NNMT inhibitor in metabolic pharmacology

Discussions of novel pharmacological targets in obesity and metabolic syndrome are today dominated by incretins — semaglutide, tirzepatide, retatrutide — all acting on the GLP-1 axis and related receptors. Far less space in the mainstream conversation is given to an enzyme called NNMT (Nicotinamide N-Methyltransferase) — a metabolic pathway rarely discussed outside the narrow niche of research into obesity and NAD+ metabolism. 5-amino-1MQ is the first molecule published in the literature with the profile of a selective NNMT inhibitor with good membrane permeability — a pharmacological tool whose significance lies not in directly “burning fat” but in intervening in the intracellular balance of methylation and coenzymes.

5-amino-1MQ (5-amino-1-methylquinolinium iodide) is a small organic molecule from the class of selective NNMT inhibitors. It has been studied in mouse models of obesity and metabolic syndrome and in cell cultures of adipocytes. It has no marketing authorisation as a medicine in any jurisdiction, and there are no published clinical data in humans.

Regulatory note — a critical distinction

5-amino-1MQ operates within a single legal status only — as a research reagent (Research Use Only) for laboratory research into NNMT pharmacology and NAD+ metabolism. The molecule is not an authorised medicine, is not a food supplement, and has no EFSA authorisation. Efficacy data come solely from animal models (mice fed a high-fat diet — HFD) and cell cultures. There are no published clinical studies in humans whatsoever.

What 5-amino-1MQ is — pharmacological class

5-amino-1MQ is a small organic molecule — not a peptide, not a protein, not a hormone. It is a compound of quaternary ammonium salt character, synthesised as a pharmacological tool for research into the enzyme NNMT. The molecule was first described in the literature in 2018 in the context of diet-induced obesity — as the first published NNMT inhibitor with sufficient selectivity and membrane permeability to be tested in an animal model in vivo. In the One Peptides catalogue the molecule is available as 5-amino-1MQ 50 mg.

Chemical characteristics

What NNMT is — a little-known but important enzyme

NNMT — Nicotinamide N-Methyltransferase — is an enzyme that catalyses one seemingly simple biochemical reaction: it transfers a methyl group from SAM (S-adenosylmethionine) to nicotinamide (NAM), forming 1-methylnicotinamide (1-MNA) and SAH (S-adenosylhomocysteine).

Three consequences of high NNMT activity

Depletion of the NAD+ pool. Nicotinamide (NAM) is one of the main precursors of the coenzyme NAD+ in the salvage pathway. If NAM is methylated by NNMT to 1-MNA, it no longer returns to the salvage pathway — it leaves the pool of available NAD+ precursors. This is a fundamental point of contact with NAD+ pharmacology and the longevity field, discussed in more detail in the guide to NMN and supplementation with NAD+ precursors.

Depletion of SAM — disruption of methylation. SAM (S-adenosylmethionine) is the universal methyl donor in the cell. NNMT consumes SAM as a co-substrate in every reaction methylating NAM. High NNMT activity may therefore compete for the SAM pool with other methyltransferases, affecting the epigenetic and metabolic status of the cell.

A rise in 1-MNA as a marker. 1-MNA, the product of the NNMT reaction, is itself a metabolite with a signalling role — its elevated concentration in plasma and adipose tissue has been observed in people with obesity and metabolic syndrome.

NNMT in the adipose tissue of people with obesity

A classic study by Kraus et al. (2014), published in Nature, showed that knockdown of NNMT in mouse adipose tissue protects against diet-induced obesity — mice with suppressed NNMT expression, fed a high-fat diet, had lower adipose tissue mass, higher energy expenditure and better insulin sensitivity compared with control mice.

Mechanism — NNMT inhibition and adipocyte metabolism

Once administered, 5-amino-1MQ blocks the enzymatic activity of NNMT inside the adipocyte. The mechanistic consequences, described in the 2018 papers:

Preservation of the NAD+ pool. Nicotinamide is not methylated to 1-MNA and remains available for the salvage pathway. NNMT inhibition therefore protects the NAD+ pool on the side of precursor catabolism — it acts “from the other side” relative to direct supplementation with precursors (NMN, NR).

Normalisation of methylation status. Less SAM is consumed on the methylation of NAM, so more SAM remains available for other methyltransferases — including those responsible for the methylation of DNA and histones.

Modulation of adipogenesis and lipid metabolism. In mouse models fed a high-fat diet (HFD), administration of 5-amino-1MQ was associated with a reduction in body weight, a reduction in white adipose tissue mass and improved insulin sensitivity.

Limit of extrapolation. All of the above mechanisms have been described in mouse models and cell cultures. There are no published data confirming this mechanistic profile in humans.

5-amino-1MQ and NAD+ metabolism — a bridge to longevity

Supplementation with NAD+ precursors — mainly NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — is the dominant strategy for raising the cellular NAD+ pool. This strategy acts “from the top” — by supplying more precursors to the salvage pathway.

NNMT inhibition is an alternative route — it acts “from the other side”. Instead of supplying more NAM/NMN, it protects the molecules already in the cell from unwanted catabolism by NNMT. The hypothetical logic: if the cell loses NAM to the production of 1-MNA by NNMT, then inhibiting NNMT preserves NAM for the salvage pathway and — indirectly — protects the NAD+ pool.

This complementarity of mechanisms opens up the speculative area of possible synergies: NAD+ precursors (NMN, NR) + an NNMT inhibitor (5-amino-1MQ) could, in theory, act additively. There are, however, no published clinical studies testing this hypothesis in humans.

Research on 5-amino-1MQ and NNMT

What is missing from the literature

• No published clinical studies (phase 0/I/II/III) involving humans
• No pharmacokinetic data in humans
• No long-term safety data
• No head-to-head comparative studies with NMN, NR or other NAD+ modulators

Regulatory status and safety

5-amino-1MQ has no marketing authorisation as a medicine in any known jurisdiction — neither the EMA, nor the FDA, nor the PMDA, nor any other major regulatory body has authorised the molecule as a medicinal product. The full context of the legal status of research reagents is set out in the article on EU law. Nor does it have food supplement status — EFSA has issued no opinion.

WADA and the anti-doping context

The “NNMT inhibitors” class is not currently listed directly as a category of prohibited substances — which does not mean that specific molecules of this class could not be covered by general clauses (e.g. S0 — substances not approved for human medical use).

What we do not know about safety in humans

• The long-term effect on DNA and histone methylation status — unknown
• The effect on tissues other than adipose tissue — poorly characterised
• Interactions with NAD+ precursors — the speculative synergy is unconfirmed
• The pharmacokinetic profile in humans — unknown

5-amino-1MQ as a research reagent

In the One Peptides catalogue, 5-amino-1MQ functions as a chemical reagent in the form of 50 mg per vial — intended for laboratory research into NNMT pharmacology, NAD+ metabolism in cell and mouse models, and methylation modulation in adipocyte cultures. Quality standards: HPLC ≥98%, MS confirmation, COA per batch, cold chain. A full description of the QA process is given in quality testing and certificates.

Frequently asked questions

Does 5-amino-1MQ aid weight loss in humans?

There are no published clinical data confirming that 5-amino-1MQ brings about a reduction in body weight in humans. All reported effects on body weight and adipose tissue come solely from mouse models.

What is NNMT and why is it a therapeutic target?

NNMT — Nicotinamide N-Methyltransferase — is an enzyme that transfers a methyl group from SAM to nicotinamide (NAM), forming 1-methylnicotinamide (1-MNA). High levels of NNMT have been observed in the adipose tissue of people with obesity, and NNMT knockdown in mice protects against diet-induced obesity (Kraus 2014, Nature).

5-amino-1MQ and NAD+ — how are they connected?

NNMT consumes nicotinamide (NAM) — one of the main precursors of the coenzyme NAD+ in the salvage pathway. NNMT inhibition can therefore act “from the other side” relative to direct supplementation with NAD+ precursors (NMN, NR) — instead of supplying more NAM, it protects the one already in the cell.

How does 5-amino-1MQ differ from NMN?

NMN (nicotinamide mononucleotide) is an NAD+ precursor — a substrate for the enzymes of the salvage pathway. It acts “from the top” — by enriching the pool of precursors. 5-amino-1MQ is an enzyme inhibitor (NNMT) that protects the NAD+ precursors already present in the cell from metabolic leakage. Both mechanisms are complementary, but address different control points.

Is 5-amino-1MQ on the WADA list?

The “NNMT inhibitors” class is not currently listed directly as a category of prohibited substances on the WADA List, but specific molecules may be subject to the general clauses of the List. An athlete or researcher working in an anti-doping context should independently verify the current WADA guidance.

Related content in the knowledge base

5-amino-1MQ belongs to the group of compounds studied in relation to non-incretin pathways. This group also covers: BAM-15 (mitochondrial uncoupler), SLU-PP-332 (ERR pan-agonist — “exercise mimetic”), Tesofensine (triple monoamine reuptake inhibitor — Saniona’s pharmaceutical candidate in phase III). Four different pharmacological mechanisms, the same therapeutic horizon.

5-amino-1MQ stands out within this group in that it also constitutes a bridge to the longevity area — where NMN, NAD+, sirtuins and the pharmacology of healthy ageing mechanisms are discussed. NNMT inhibition is an alternative route for modulating the NAD+ pool — complementary to supplementation with the precursors NMN/NR.

By contrast, the incretin group comprises the classic compounds: semaglutide, tirzepatide, retatrutide, CagriSema. Together, these two groups form a broad map of anti-obesity pharmacology. A full overview of the class is given in the guide to GLP-1 peptides and in the article on the incretins GLP-1, GIP and glucagon.

Summary

5-amino-1MQ is a selective inhibitor of the enzyme NNMT — the first small organic molecule published in the literature that, with good membrane permeability, blocks Nicotinamide N-Methyltransferase, the enzyme that catalyses the methylation of nicotinamide to 1-MNA. NNMT inhibition protects the nicotinamide pool — the main precursor of NAD+ in the salvage pathway — and normalises the methylation status of the cell.

In mouse models of obesity induced by a high-fat diet (HFD), 5-amino-1MQ was associated with a reduction in body weight, a reduction in white adipose tissue mass and improved insulin sensitivity (Neelakantan 2018, Kannt 2018). All data on 5-amino-1MQ come solely from mouse models and cell cultures. There are no published clinical studies in humans whatsoever.

Disclaimer

In the One Peptides catalogue, 5-amino-1MQ functions solely as a chemical reagent intended for laboratory research (Research Use Only). It is not a medicinal product, a food supplement or a foodstuff. All reported efficacy effects come from mouse models and cell cultures — they have not been confirmed in humans.

Bibliography

1. Neelakantan H et al. (2018). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice
2. Kannt A et al. (2018). A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders
3. Kraus D et al. (2014). Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity
4. Pissios P (2017). Nicotinamide N-Methyltransferase: more than a vitamin B3 clearance enzyme
5. Roberti A, Fernández AF, Fraga MF (2021). Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation

Bartosz BartczakPhysiotherapist, Personal Trainer

Physiotherapist with 20 years of clinical experience, graduate of Poznan University of Medical Sciences. Founder of One Peptides and lead author of clinical-perspective content.

See Full Bio ›